Category 2A Recommendation*
Olaratumab (LARTRUVO) in combination with doxorubicin
NCCN Guidelines for STS recommend olaratumab (LARTRUVO) in combination with doxorubicin as a treatment option (with a category 2A recommendation)* in adult patients with STS with a histologic subtype for which an anthracycline-containing regimen is appropriate.
*Category 2A recommendation is based on lower-level evidence and there is uniform NCCN consensus that the intervention is appropriate.
The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Reference: 1. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed March 14, 2017. To view the most recent and complete version of the guidelines, go online to http://nccn.org.
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Please see full Prescribing Information for LARTRUVO.
OR HCP ISI 19OCT2016
You are now leaving the www.LARTRUVO.com website.